SLC5A2 and diabetes mellitus: A case series by Shah et al. and another by Ray et al. described four nondiabetic patients and three with diabetes who experienced marked improvement in serum magnesium levels following initiation of SGLT2 inhibitors, without changes in FEMg, suggesting nonrenal mechanisms, such as intestinal absorption [4, 8].